Alzheimer s DiseaseTeDIMONCT07367880
The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)
An observational study of Alzheimer s Disease, run by University Hospital, Grenoble at 1 site in France.
Trial summary
The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments. Read more about this study
- Who is it for?
- Ages 50 to 95 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer s Disease
- What is being tested?
- Identification and naming task
- How many people
- 220 participants
- Where
- 1 siteFrance
- Study dates
- 23 Feb 2026to 1 Feb 2032
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 95 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants in the MA group will be selected from among patients attending memory consultations at the CMRR at the CHU Grenoble-Alpes (active file within the department) or from among patients referred to the CMRR by a doctor not practicing at the CMRR (general practitioners or specialists such as neurologists). Healthy elderly participants will be recruited from among those accompanying patients being monitored at the CMRR.
Who may be able to join
- Alzheimer's disease:
- Age ≥ 50 years and older
- Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.
- Score 18≤ MMSE ≤26
- Controls:
- Age ≥ 50 years and older
- MMSE score ≥ 26 For all subjects
- No objection from the participant
Who cannot join
- Alzheimer's disease:
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP
- Controls:
- Memory complaints
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects
- Significant neurological or psychiatric history
Show all 10Show fewer
- Taking psychotropic medication (neuroleptics)
- Poor command of the French language, comprehension difficulties
- Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)
- Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Grenoble Alpes
Grenoble
Aurélie TRUFFOT, 0786498337, atruffot@chu-grenoble.fr
Aurélie TRUFFOT
About this study
The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.
- Conditions
- Alzheimer s Disease
- Being tested
- Identification and naming task
- Keywords
- unique entities, denomination, identification, landmarks
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Identification and naming taskOther
Task of identification and naming of landmarks and celebrities
| Study group | Role | What they receive |
|---|---|---|
| People with Alzheimer Disease | Not described Receives: Other: Identification and naming task | |
| Healthy elderly people | Not described Receives: Other: Identification and naming task |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference between the two groups in the identification and naming task involving famous landmarks
show a significant difference in performance between the two groups in the identification and naming task involving famous landmarks
Measured: 1 month
Secondary outcomes (1)
Development and standardization of a new tool for screening for naming disorders and visual identification of unique entities.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start23 Feb 2026
- Primary completion1 Feb 2031 (estimated)
- Study completion1 Feb 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer s DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 220 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07367880
- Sponsor's protocol ID
- 38RC25.0190_TeDIMO
- Other IDs
- 2025-A01292-47
- Acronym
- TeDIMO
- Status last verified
- May 2026
- First submitted
- 15 Dec 2025
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)
- ClinicalTrials.gov ID
- NCT07367880
- Acronym / sponsor ID
- TeDIMO / 38RC25.0190_TeDIMO
- Conditions
- Alzheimer s Disease
- Keywords
- unique entities, denomination, identification, landmarks
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 23 Feb 2026 (actual)
- Primary completion
- 1 Feb 2031 (estimated)
- Study completion
- 1 Feb 2032 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Month
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| People with Alzheimer Disease | – | Other: Identification and naming task |
| Healthy elderly people | – | Other: Identification and naming task |
Who may qualify
- Ages
- 50 to 95 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants in the MA group will be selected from among patients attending memory consultations at the CMRR at the CHU Grenoble-Alpes (active file within the department) or from among patients referred to the CMRR by a doctor not practicing at the CMRR (general practitioners or specialists such as neurologists). Healthy elderly participants will be recruited from among those accompanying patients being monitored at the CMRR.
Key inclusion criteria (8 listed)
- Alzheimer's disease:
- Controls:
Key exclusion criteria (10 listed)
- Alzheimer's disease:
- Controls:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Identification and naming taskTask of identification and naming of landmarks and celebrities | Other | Healthy elderly people, People with Alzheimer Disease |
Primary outcome
Difference between the two groups in the identification and naming task involving famous landmarks
Time frame: 1 month
show a significant difference in performance between the two groups in the identification and naming task involving famous landmarks
1 secondary outcome
Development and standardization of a new tool for screening for naming disorders and visual identification of unique entities.
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
Related trials for Alzheimer s Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Not yet recruitingObservational study
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer s Disease, run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sabrina Iannuzzi, Neuropsychologist (+334.76.76.57.90, siannuzzi@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference between the two groups in the identification and naming task involving famous landmarks (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.